RT Journal Article
SR Electronic
T1 Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20088757
DO 10.1101/2020.05.05.20088757
A1 Davido, Benjamin
A1 Lansaman, Thibaud
A1 Lawrence, Christine
A1 Alvarez, Jean-Claude
A1 Bouchand, Frédérique
A1 Moine, Pierre
A1 Perronne, Véronique
A1 Gal, Aurelie Le
A1 Annane, Djillali
A1 Perronne, Christian
A1 De Truchis, Pierre
A1 on behalf of the COVID-19 RPC Team
YR 2020
UL http://medrxiv.org/content/early/2020/05/20/2020.05.05.20088757.abstract
AB “The authors have withdrawn this manuscript and do not wish it to be cited. Because of controversy about hydroxychloroquine and the retrospective nature of their study, they intend to revise the manuscript after peer review”Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04364698Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available for the journal editor on request.